Connected With Latham

Episode 111 – The Growth Rocketship: The Future of Rewards-Based Advertising With Fetch

Episode 110 – Spotlight on US State Healthcare Transaction Review Laws

Episode 109 – Drug Pricing and Market Access: Key Takeaways From 2025 and Outlook for 2026

Episode 108 – UK FinReg Focus Areas in 2026

Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape

Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards

Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services

Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity

Episode 100 – The Leeds Reforms: Implications for UK Financial Services

Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting

Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation

Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech

Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE

Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant

Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends

Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets

Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?

Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?

Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US

Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?

Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference

Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?

Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration

Episode 78 – UK FinReg Focus Areas in 2024: ESG

Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals

Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence

Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms

Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture

Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence

Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms

Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024

Episode 70 – UK FinReg Focus Areas in 2024: Investment Research

Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel

Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?

Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity

Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform

Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?

Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?

Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?

Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?